Titan Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

David Lazar

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	27.6%
Permanencia del CEO	1.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	1.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Lazar en comparación con los beneficios de Titan Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$406k	-US$6m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$726k	US$152k	-US$10m

Compensación vs. Mercado: La compensación total de David($USD1.47M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).

Compensación vs. Ingresos: La compensación de David ha aumentado mientras la empresa no es rentable.

CEO

David Lazar (32 yo)

1.8yrs

Permanencia

US$1,473,180

Compensación

Mr. David Elliot Lazar is Chairman and CEO of OpGen, Inc. from March 25, 2024. Mr. Lazar serves as Chief Executive Officer, President, Secretary, Chief Financial Officer, Director of UBuyHoldings, Inc. sin...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Katherine Beebe-DeVarney	President	4.4yrs	US$602.11k	0.36% $ 22.6k
David Natan	Independent Director	1.8yrs	US$251.16k	0.36% $ 22.6k
Matthew McMurdo	Independent Director	1.8yrs	US$239.07k	0.36% $ 22.6k
Avraham Ben-Tzvi	Independent Director	1.8yrs	US$239.91k	0.36% $ 22.6k
Eric Greenberg	Independent Director	1.8yrs	US$244.07k	0.36% $ 22.6k
Brynner Chiam	Independent Director	less than a year	US$9.38k	sin datos
Gim Seow	Independent Chairman of the Board	less than a year	US$9.38k	0% $ 0

1.8yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de TTNP no se considera experimentada (1.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Titan Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. Announces Board Changes

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Recent updates

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020